Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Patrick Forde, M.B.B.Ch.

Headshot of Patrick Forde
  • Director, Thoracic Oncology Clinical Research Program
  • Associate Professor of Oncology
Male

Languages: English, Irish

Expertise

Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma, Non-Small Cell Lung Cancer, Pulmonary Carcinoid Tumors, Small Cell Lung Cancer ...read more

Research Interests

Lung Cancer; Mesothelioma; Clinical Investigation

Locations

Skip Viragh Outpatient Cancer Center

201 N. Broadway
Baltimore, MD 21287 map
Phone: 410-955-8893 | Fax: 410-614-9334

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 21224 map
Phone: 410-550-1711 | Fax: 410-550-1116

Background

Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of Clinical Research for lung cancer, mesothelioma, and other thoracic cancers at Johns Hopkins.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for earlier stage lung cancer and his work has led to the development of several ongoing phase 3 trials. 

He leads international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins. He is focused on providing compassionate, state of the art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners and dedicated staff.

...read more

Titles

  • Director, Thoracic Oncology Clinical Research Program
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MBBCh; Royal College of Surgeons in Ireland (2004)

Residencies

  • Medical Oncology; Beaumont Hospital (2009)
  • Medical Oncology; Mater Misericordiae University Hospital (2008)
  • Internal Medicine; Royal College of Physicians Ireland (2007)

Fellowships

  • Medical Oncology; Cork University Hospital (2010)
  • Oncology; Johns Hopkins University School of Medicine (2014)
  • Medical Oncology; St James's Hospital (2011)

Research & Publications

Selected Publications

View all on PubMed

Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. PMID:29658848

Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018 Aug 1;29(8):1853-1860 PMID: 29982279

Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225. PMID: 30541742

Rosner S, Reuss JE, Forde PM. PD-1 Blockade in Early-Stage Lung Cancer. Annu Rev Med. 2019 Jan 27;70:425-435. PMID: 30355264

Reuss JE, Forde PM. Neoadjuvant Nivolumab plus Ipilimumab in Resectable Non-Small Cell Lung Cancer. J Immunother Cancer. 2020 Sep;8(2):e001282. PMID: 32554619

Activities & Honors

Honors

  • Fellowship Award, International Association for the Study of Lung Cancer (IASLC), 2013
  • Career Development Award, LUNGevity Lung Cancer Foundation , 2014
  • Paul Carbone MD Fellowship Award, 2013
  • Director's Teaching Award in Clinical Science, SKCCC, 2014
  • AACR-SU2C Phillip A. Sharp Innovation in Collaboration Award, 2016
  • ESMO Travel Award, 2016
  • Principal Investigator, Translational Team Science Award, US Department of Defense, 2020
  • SITC Team Science Award, Society for Immunotherapy of Cancer, 2020

Memberships

  • American Society of Clinical Oncology
  • International Association for the Study of Lung Cancer
  • Society for Immunotherapy of Cancer

Videos & Media

Recent News Articles and Media Coverage

Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma, ASCO Post (July 10, 2020)

New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer. Interviewed for article reporting on Forde et al. TIME magazine (April 16, 2018), NEJM paper

New studies show hope for turning immune system against lung cancer. Interviewed for article reporting on Forde et al. USA Today (April 16, 2018) NEJM paper

Drug reduces size of some lung cancer tumors, relapse rate after surgery. Interviewed for article reporting on Forde et al. ScienceDaily.com (April 16, 2018) NEJM paper

Interviewed for article on my research entitled "Pre-op delivery of checkpoint inhibitor shrinks tumors in nearly half of patient" Oncology Times (August 25, 2017)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button